Jarrett Jennifer 4

What Happened

• Jennifer Jarrett, a director of Syndax Pharmaceuticals (SNDX), was granted 24,000 restricted stock units (RSUs) on February 4, 2026. The grant price is reported as $0.00 (award), so there was no cash paid by the insider at grant.

Key Details

• Transaction type/code: Award (A) — Restricted Stock Units (RSUs).
• Grant date: 2026-02-04; Form 4 filed: 2026-02-06 (filed timely within the standard 2-business-day window).
• Number of RSUs granted: 24,000; grant price: $0.00 (no upfront cash consideration).
• Shares owned after transaction: Not specified in the filing.
• Footnote: The RSUs vest one year from the grant date. The shares underlying these RSUs will not be delivered and may not be transferred or sold until the earlier of a separation from service, death, disability, or a change in control.

Context

• An RSU award is a compensation grant, not an open-market purchase or sale. It does not represent immediate proceeds or a cash outlay by the insider and typically vests over time or upon specified events.
• Awards like this are common for directors and executives as part of compensation and do not by themselves indicate a buy or sell market signal.